SLC5A2 and acute kidney injury: Currently, three randomized controlled trials are underway, MERCURI-2, VERTIGO, and STENOTYPE, to further investigate the impact of perioperative SGLT2 inhibitors on acute kidney injury (AKI) outcomes [18-20].